MedTrace Logo

A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma

NCT01572519 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2020-11-20

No results posted yet for this study

Summary

The purpose of this study is to determine the safety, pharmacokinetics, and preliminary efficacy information of JNJ-40346527 in patients with relapsed or refractory Hodgkin lymphoma.

Conditions

  • Relapsed or Refractory Hodgkin Lymphoma

Interventions

DRUG

Phase 1, Cohort 1

Type=exact number, unit=mg, number=150, form=capsule, route=oral use. Capsule is taken once daily.

DRUG

Phase 1, Cohort 2

Type=exact number, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once daily.

DRUG

Phase 1, Cohort 3

Type=exact number, unit=mg, number=450, form=capsule, route=oral use. Capsule is taken once daily.

DRUG

Phase 1, Cohort 4

Type=exact number, unit=mg, number=600, form=capsule, route=oral use. Capsule is taken once daily.

DRUG

Phase 2

JNJ-40346527 at the recommended dose determined in Phase 1

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-17
Primary Completion
2013-08-13
Completion
2013-08-13

Countries

  • France
  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01572519 on ClinicalTrials.gov